Legacy Capital Group California Inc. Purchases Shares of 21,162 Roivant Sciences Ltd. $ROIV

Legacy Capital Group California Inc. purchased a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 21,162 shares of the company’s stock, valued at approximately $459,000.

Several other hedge funds have also bought and sold shares of ROIV. Jones Financial Companies Lllp grew its holdings in Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after purchasing an additional 1,148 shares during the period. Allworth Financial LP grew its holdings in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares during the period. Bessemer Group Inc. grew its holdings in Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the period. Osaic Holdings Inc. grew its holdings in Roivant Sciences by 204.2% during the second quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock valued at $65,000 after purchasing an additional 3,882 shares during the period. Finally, Aster Capital Management DIFC Ltd grew its holdings in Roivant Sciences by 75.8% during the third quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company’s stock valued at $67,000 after purchasing an additional 1,900 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Down 3.5%

NASDAQ ROIV opened at $28.14 on Friday. The firm has a market cap of $20.14 billion, a price-to-earnings ratio of -24.05 and a beta of 1.20. The business has a 50-day moving average price of $28.22 and a 200-day moving average price of $23.50. Roivant Sciences Ltd. has a twelve month low of $10.58 and a twelve month high of $30.33.

Wall Street Analysts Forecast Growth

ROIV has been the subject of several recent research reports. Sanford C. Bernstein initiated coverage on Roivant Sciences in a report on Friday, March 20th. They set an “outperform” rating and a $35.00 price target for the company. HC Wainwright upped their price objective on Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Citigroup upped their price objective on Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Guggenheim upped their price objective on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, Piper Sandler upped their price objective on Roivant Sciences from $22.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 16th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.55.

Insider Buying and Selling

In related news, Director Melissa B. Epperly sold 41,861 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $28.68, for a total value of $1,200,573.48. Following the sale, the director directly owned 15,804 shares in the company, valued at approximately $453,258.72. The trade was a 72.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Matthew Gline sold 289,774 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $29.16, for a total value of $8,449,809.84. Following the completion of the sale, the chief executive officer owned 16,736,116 shares in the company, valued at $488,025,142.56. This represents a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 5,085,398 shares of company stock valued at $139,215,946 in the last ninety days. Company insiders own 10.80% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.